| 摘要 |
A chronic hepatitis C antiviral pharmaceutical composition comprises an antivirally effective amount of a polymer-cytokine conjugate in association with a pharmaceutically acceptable carrier, the cytokine may be, for example, interferon alpha or interferon alpha-2b, and the polymer of the conjugate may be, for example, polyethylene glycol.
|
